User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

9928

Interactions with Platform & by Email *

INTERACTIONS

1390

Unique # Participated *

PARTICIPANTS

298

Responses Validated *

VALIDATIONS

56

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
1. Internal Analgesics.....I-3
Aspirin.....I-3
Acetaminophen.....I-3
Ibuprofen.....I-3
Others.....I-3
2. External Analgesics.....I-3
  
   Pain Therapeutic Market.....II-4
Analgesics Market - Offering Immense Potential.....II-4
Internal Analgesics – The Largest & Fastest Growing Market.....II-4
1$100
   Liquid Analgesics Register Rapid Growth.....II-5
Neuropathic Pain - Unexplored.....II-5
Ibuprofen Scoring High.....II-5
External Analgesics – Loosing Sheen.....II-5
1$100
   Topical Analgesics Market: Current Picture.....II-6
Competitive Scenario.....II-6
Global Analgesics Market (2007): Leading Analgesics Brands by Manufacturer.....II-6
1$100
   A Brief History.....II-7
Analgesics.....II-7
Definition.....II-7
Types of Pain.....II-7
Acute Pain.....II-7
1$100
   Chronic Pain.....II-8
Drugs Combating Pain.....II-8
Local Anesthetics.....II-8
Narcotic Opioids.....II-8
1$100
   Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).....II-9
Types of NSAIDS.....II-9
1$100
   Common NSAIDs.....II-101$100
   Clinical Use........II-11
Side Effects........II-11
1$100
   Aspirin.....II-12
The Wonder Drug........II-12
PolyAspirin: The Safer and More Potent Polymer Variant of Aspirin.....II-12
Mode of Action.....II-12
1$100
   Contraindications.....II-13
Acetaminophen.....II-13
Acetaminophen Protects Heart Muscle.....II-13
Acetaminophen Reduces Incidence of Ovarian Cancer.....II-13
1$100
   Ibuprofen, Ketoprofen and Naproxen.....II-14
Combination Analgesics.....II-14
Table 1: Opioid Analgesics Market: Percentage Share of Opioid/Acetaminophen Combination Products in the Opioid Script Volume (includes corresponding Graph/Chart).....II-14
1$350
   OTC Analgesics: An Overview.....II-151$100
   Escalating R&D Costs: A Boon or Bane?.....II-16
Timeline of the Drug Approval Process.....II-16
Cox II Crisis Tarnishes Industry Growth.....II-16
1$100
   Novel Therapies to Propel Opioid and Non-Opioid Therapies.....II-17
Rx-to-OTC Switch.....II-17
Why Consumers Prefer OTC Drugs?.....II-17
Development of Analgesic Tripeptides.....II-17
1$100
   PLx Initiates Clinical Trial For Aspirin-PC.....II-18
Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials.....II-18
1$100
   Victory Pharma Unveils Naprelan Dose Card.....II-19
Nutra Pharma Commences Online Sales of Cobroxin.....II-19
Nutra Pharma to Introduce Nyloxin Rx.....II-19
Dr Reddy’s Rolls Out Finrid.....II-19
1$100
   MIP Technologies and Supelco Introduce Unique SPE Product.....II-20
Novartis Introduces Voltaren AC Product Line.....II-20
ProEthic Pharmaceuticals Releases Ibudone for Acute Pain Management.....II-20
Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain Management.....II-20
Teva Pharmaceutical Announces the Launch of Fentanyl Transdermal System.....II-20
1$100
   Dr. Reddy's Laboratories Introduces Supanac NSAID Drug.....II-211$100
   Mallinckrodt Introduces Magnacet™ Tablets for Pain Management.....II-22
Wockhardt to Launch New Painkiller.....II-22
Paladin Labs and Labopharm Introduce Tridural™.....II-22
Shionogi & Co Introduces OxiNorm Powder 0.5%.....II-22
McNeil Brings Chewable TYLENOL® GoTabs Tablets.....II-22
1$100
   Barr Unveils Generic Version of ACTIQ®.....II-23
Novartis Launches Voltarol Pain-Eze Emulgel......II-23
TheraQuest Launches TQ-1017.....II-23
Mentholatum Company Introduces WellPatch Deep Heat Patch .....II-23
1$100
   Par Pharmaceutical Secures Approval for Marketing Tramadol ER.....II-24
Cipher Acquires Tentative Approval for Tramadol ER Capsules.....II-24
Lannett Receives Approval for Developing Hydromorphone Hydrochloride Tablets.....II-24
King Pharmaceuticals Receives Approval for Embeda Pain-Relief Capsules.....II-24
1$100
   Sangart Secures EC’s Orphan Drug Designation for MP4CO.....II-25
Biovail Secures Canadian Approval for Ralivia.....II-25
Elite Pharmaceuticals and PharmaNetwrok Receive FDA Approval.....II-25
1$100
   China Life Insurance Inks Agreement with Sino Biopharmaceutical.....II-26
Azur Pharma Inks Agreement with Elan Pharmaceuticals.....II-26
Pfizer Acquires Wyeth.....II-26
Taisho Pharmaceutical Takes Over OTC Drugs Business of Bristol-Myers Squibb.....II-26
1$100
   Piramal Healthcare Acquires Minrad International.....II-27
Biocon Acquires Bulk Pharmaceuticals Unit of Hindujas.....II-27
Abbott Acquires PG110 from PanGenetics.....II-27
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick.....II-27
WraSer Acquires e5 Pharma’s Trezix.....II-27
1$100
   Astellas Acquires Exclusive rights to Pain-Relief Drug from Neuroges.....II-28
Henan Lingrui Pharma Commences Construction of New Analgesic Factory.....II-28
Labopharm Europe Enters into Agreement with Merck Sharp & Dohme.....II-28
Cumberland Pharmaceuticals Enters into a Commercialization Agreement with DB Pharm
  Korea.....II-28
1$100
   Cumberland Pharmaceuticals Inks an Exclusive Agreement with Phebra.....II-29
Mallinckrodt Acquires Rights of Exalgo Extended-Release Tablets from Neuromed.....II-29
Labopharm Europe and Grunenthal Sign Distribution and Supply Agreement.....II-29
Timm Medical and Ferring Co-promote Prosed DS in the US.....II-29
Competitive Technologies and Fintrade Medical Ink Sales and Distribution
  Agreement.....II-29
1$100
   Accumetrics and Endotech Ink Exclusive Distribution Agreement.....II-30
Astellas and NeurogesX Sign Distribution and Marketing Agreement.....II-30
Akela Pharma Inks Agreement with Teikoku Seiyaku.....II-30
Medical Nutrition Inks Exclusive Licensing Agreement with DSE Healthcare.....II-30
1$100
   Echo Therapeutics Inks a Licensing Deal with Ferndale Pharma.....II-31
Circ Pharma Signs a Development Agreement with Elan.....II-31
Orexo Inks Distribution Agreement with Neopharm.....II-31
1$100
   Orexo Inks Agreement with NovaMed Pharmaceuticals.....II-32
Pharmos and Reperio Enter into Agreement.....II-32
Caraco Pharmaceutical Launches Oxycodone Hydrochloride Tablet.....II-32
Purdue Pharma Provides Labopharm’s RYZOLT.....II-32
1$100
   Bayer Acquires Sagmel’s OTC Business.....II-33
E5 Pharma Receives Approval from FDA.....II-33
Pharmaceutical Associates Receives Approval from FDA.....II-33
Concord Receives New Drug Approvals.....II-33
Hisamitsu Receives Approval for SALONPAs®.....II-33
Johnson & Johnson Submits NDA to FDA.....II-33
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural.....II-33
1$100
   Akela Extends Agreement with Janssen.....II-34
Daiichi and Lead Chemical Receives Approval for Loxonin? Tape.....II-34
Tokio Marine Capital Acquires Showa Yakuhin Kako.....II-34
Corgenix Collaborates with Randox Laboratories.....II-34
Corgenix Receives EPO Approval for Aspirin Resistance Method.....II-34
IOL to Expand Production Capacity.....II-34
1$100
   American Oriental Bioengineering Partners with China Aoxing.....II-35
Abraxis Takes Over Shimoda and its Subsidiary Company.....II-35
Church & Dwight Snaps Up Del Pharmaceuticals from Coty.....II-35
Sosei Group Corp Re-Acquires Rights to Commercialize AD 923.....II-35
ProStrakan Group Inks Agreement with Paladin Labs.....II-35
1$100
   Anika Therapeutics Inks Distribution Agreement with DePuy Mitek.....II-36
Wyeth Acquires ThermaCare Brand from P&G.....II-36
Albemarle Appoints Dr. Reddy’s as Distributor of Bulk Ibuprofen API.....II-36
1$100
   Competitive Technologies and ELS Join Forces to Distribute Pain Management
  Device.....II-37
Altea Therapeutics Partners with Hospira.....II-37
Paladin Inks Co-Promotion Deal with Nycomed.....II-37
1$100
   AstraZeneca to Divest OTC Portfolio.....II-381$100
   Ranbaxy Receives Approval from FDA.....II-39
Wockhardt Receives FDA Approval for DPN + APAP.....II-39
Alpharma to Market Flector® Patch in the US.....II-39
Auriga and Mikart Inks Agreement to Market Codein.....II-39
Watson Receives FDA Approval for Oxycodone Hydrochloride and Ibuprofen.....II-39
Labopharm’s Tramadol Receives Approval in Canada.....II-39
1$100
   Lion Acquires BUFFERIN® Trademark Rights.....II-40
Grunenthal’s Extends Licensing Agreement with Ortho-McNeil.....II-40
China Aoxing Pockets LRT.....II-40
Anesiva Inks Joint Venture Agreement Wanbang.....II-40
Beijing Med-Pharm Inks Agreement with Lotus Healthcare.....II-40
LAB International Inks Licensing Agreement with Janssen Pharmaceutica.....II-40
1$100
   Three Sixty Pockets Rockford-Montgomery Labs.....II-41
Antares Enters into License and Development Agreement for Opioid Analgesic.....II-41
Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand Portfolio.....II-41
IntelliPharmaCeutics Inks Agreement with Larasan.....II-41
Ranbaxy and Ethypharm Ink In-licensing Agreement.....II-41
Elite Collaborates with TPN to Co-develop Analgesic Drug.....II-41
1$100
   Novartis Acquires Hexal Company and Major Stake in Eon Labs ......II-42
NovaDel Pharma Receives Patent for Buccal Sprays Technology.....II-42
Auxilium Pharmaceuticals Enters into a Licensing Agreement with PharmaForm .....II-42
EC Sanctions Sale of Elan’s Prialt.....II-42
1$100
   EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc.....II-43
Reckitt Benckiser plc Acquires Boots Healthcare International .....II-43
1$100
   Bayer Consumer Care (US).....II-44
Johnson & Johnson (US).....II-44
McNeil Consumer Healthcare (Canada).....II-44
Novartis International AG (Switzerland).....II-44
1$100
   Pfizer Inc. (US).....II-45
Reckitt Benckiser Group Plc (UK).....II-45
Sanofi Aventis S.A. (France).....II-45
1$100
   Table 2: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-461$350
   Table 3: World Historic Review for Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-471$350
   Table 4: World 11-Year Perspective for Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-481$350
   Table 5: World Recent Past, Current & Future Analysis for Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-491$350
   Table 6: World Historic Review for Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-501$350
   Table 7: World 11-Year Perspective for Internal Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-511$350
   Table 8: World Recent Past, Current & Future Analysis for Internal Analgesics by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-521$350
   Table 9: World Historic Review for Internal Analgesics by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-531$350
   Table 10: World 11-Year Perspective for Internal Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and Others Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-541$350
   Table 11: World Recent Past, Current & Future Analysis for Aspirin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-551$350
   Table 12: World Historic Review for Aspirin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-561$350
   Table 13: World 11-Year Perspective for Aspirin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-571$350
   Table 14: World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-581$350
   Table 15: World Historic Review for Acetaminophen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-591$350
   Table 16: World 11-Year Perspective for Acetaminophen by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-601$350
   Table 17: World Recent Past, Current & Future Analysis for Ibuprofen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-611$350
   Table 18: World Historic Review for Ibuprofen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-621$350
   Table 19: World 11-Year Perspective for Ibuprofen by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010 & 2015 (includes corresponding Graph/Chart).....II-631$350
   Table 20: World Recent Past, Current & Future Analysis for Other Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 21: World Historic Review for Other Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-651$350
   Table 22: World 11-Year Perspective for Other Internal Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-661$350
   Table 23: World Recent Past, Current & Future Analysis for External Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 24: World Historic Review for External Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-681$350
   Table 25: World 11-Year Perspective for External Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-691$350
   A. Market Analysis.....II-70
Current and Future Analysis.....II-70
Pain Statistics in the US.....II-70
Industry Overview.....II-70
1$100
   Internal Analgesics.....II-71
Cox-2 Drugs in for Some Trouble.....II-71
Switch to OTC Drugs.....II-71
Table 26: US Analgesics Market (2009): Percentage Share Breakdown of Leading Manufacturers by Sales (includes corresponding Graph/Chart).....II-71
1$350
   Table 27: US Internal Liquid Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart).....II-72

Table 28: US Internal Tablet Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart).....II-72
1$350
   Table 29: Internal Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Discount Stores, Food/Drug Combination Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes corresponding Graph/Chart).....II-73
Promotional Strategies for the Internal Analgesics.....II-73
Table 30: Market for Internal Liquid Analgesics in the US by Retail Channel (2008): Percentage Share by Value Sales for Supermarkets, Drug Stores, and Discounters (includes corresponding Graph/Chart).....II-73
Pediatric Analgesics: The New Kid on the Block.....II-73
1$350
   External Analgesics.....II-74
Stretching Boundaries.....II-74
Table 31: US External Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart).....II-74

Table 32: External Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Chain drug stores, Discount stores, Food/drug combination stores, Independent drug stores, and Supermarkets (includes corresponding Graph/Chart).....II-74
Rubs, Patches: Driving the External Analgesics Market.....II-74
1$350
   Patch Relief Gaining Momentum.....II-75
B. Market Analytics.....II-75
Table 33: US Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-75
1$350
   Table 34: US Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-761$350
   Table 35: US 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-771$350
   Market Analysis.....II-78
Table 36: Canadian Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-78
1$350
   Table 37: Canadian Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-791$350
   Table 38: Canadian 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-801$350
   A. Market Analysis.....II-81
Current and Future Analysis.....II-81
Competitive Scenario in the Past.....II-81
Table 39: OTC Analgesics Market in Japan (2005): Market Shares of Leading Players by Value - Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and Others (includes corresponding Graph/Chart).....II-81
1$350
   B. Market Analytics.....II-82
Table 40: Japanese Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-82
1$350
   Table 41: Japanese Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-831$350
   Table 42: Japanese 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-841$350
   A. Market Analysis.....II-85
Current and Future Analysis.....II-85
By Product Group/Segment.....II-85
European Pain Management Market.....II-85
Generics Restrain Revenue Growth.....II-85
1$100
   Popular Brands in 2004.....II-86
Table 43: Popular Brands of Pain & Inflammation Medication in Europe (2004): Percentage Share Breakdown of Sales for Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart).....II-86
1$350
   B. Market Analytics.....II-87
Table 44: European Recent Past, Current & Future Analysis for Analgesics by Geographic Region/ Country - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-87
1$350
   Table 45: European Historic Review for Analgesics by Geographic Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-881$350
   Table 46: European 11-Year Perspective for Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-891$350
   Table 47: European Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-901$350
   Table 48: European Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2007 (includes corresponding Graph/Chart).....II-911$350
   Table 49: European 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-921$350
   A. Market Analysis.....II-93
Current and Future Analysis.....II-93
Competitive Scenario.....II-93
Table 50: Analgesics Market in France (2005): Market Share of Leading Players by Value - Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare, and Others) (includes corresponding Graph/Chart).....II-93
1$350
   B. Market Analytics.....II-94
Table 51: French Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-94
1$350
   Table 52: French Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-951$350
   Table 53: French 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart).....II-961$350
   A. Market Analysis.....II-97
Current and Future Analysis.....II-97
Competitive Scenario.....II-97
Table 54: Analgesics Market in Germany (2005): Market Shares of Leading Players by Value - Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and Others (includes corresponding Graph/Chart).....II-97
1$350
   B. Market Analytics.....II-98
Table 55: German Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-98
1$350
   Table 56: German Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-991$350
   Table 57: German 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1001$350
   A. Market Analysis.....II-101
Current and Future Analysis.....II-101
Competitive Scenario.....II-101
Table 58: Analgesics Market in Italy (2005): Market Share of Leading Players by Value - Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, and Others (includes corresponding Graph/Chart).....II-101
1$350
   B. Market Analytics.....II-102
Table 59: Italian Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-102
1$350
   Table 60: Italian Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1031$350
   Table 61: Italian 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1041$350
   A. Market Analysis.....II-105
Current and Future Analysis.....II-105
An Overview of Analgesics Market in the UK.....II-105
Distribution Scenario.....II-105
Competitive Scenario.....II-105
Table 62: Analgesics Market in the United Kingdom (2005): Market Share of Leading Players by Value - Boots Healthcare, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).....II-105
1$350
   B. Market Analytics.....II-106
Table 63: UK Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-106
1$350
   Table 64: UK Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1071$350
   Table 65: UK 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1081$350
   A. Market Analysis.....II-109
Current and Future Analysis.....II-109
Competitive Scenario.....II-109
Table 66: Analgesics Market in Spain (2005): Market Share of Leading Players by Value - Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots Healthcare, and Others (includes corresponding Graph/Chart).....II-109
1$350
   B. Market Analytics.....II-110
Table 67: Spanish Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-110
1$350
   Table 68: Spanish Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1111$350
   Table 69: Spanish 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1121$350
   Market Analysis.....II-113
Table 70: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart).....II-113
1$350
   Table 71: Rest of Europe Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1141$350
   Table 72: Rest of Europe 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1151$350
   A. Market Analysis.....II-116
Current and Future Analysis.....II-116
The OTC Analgesic Market.....II-116
OTC Analgesics Market in Asia-Pacific (2004): A Comparative Analysis of the Major
  Regions – Australia, China and South Korea.....II-116
1$100
   B. Market Analytics.....II-117
Table 73: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-117
1$350
   Table 74: Asia-Pacific Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1181$350
   Table 75: Asia-Pacific 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart).....II-1191$350
   Market Analysis.....II-120
Table 76: Latin American Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-120
1$350
   Table 77: Latin American Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1211$350
   Table 78: Latin American 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart).....II-1221$350
   Market Analysis.....II-123
Table 79: Rest of World Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-123
1$350
   Table 80: Rest of World Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-1241$350
   Table 81: Rest of World 11-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1251$350
   Canada.....II-126
France.....II-126
1$100
   Germany.....II-1271$100
   United Kingdom.....II-1281$100
   Leading Analgesics Brands for Children.....II-129
Italy.....II-129
Spain.....II-129
1$100
   Rest of Europe.....II-1307$275
   Asia-Pacific.....II-1374$175
   Latin America.....II-1411$100
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com